EastGate to receive the first non-dilutive investment tranch from the total funding up to $5 million USD as per the terms of the Definitive Agreement.
Genome Pharma is the parent company of Netris/Origin BioPharmaceuticals the company's Joint Venture Partner
Investment and Product License includes licensing fee and development costs
Terms of the Agreement reflects long term vision and supports company's business plan
Drug Development and Nutraceuticals Covered in JV.
EastGate to receive funding in tranches up to $5 million USD.
The Share Reserve with Transfer Agent has been cancelled and all remaining shares have been returned to EastGate Biotech.
Change in Direction is Welcomed by the National Advisory Council Who Represent the Franchise Base
New Management Strategy is Brilliant
Partnership to explore bringing blockchain security and other applications to our Internet of Things building automation platform.
Quarterly Revenue Increases 7X Year Over Year to $3.2 Million & Operating Cash Flow Remains Positive Through First Six Months of Combined Operations Following SolBright Acquisition